Systemic Lupus Erythematosus in Gullah Health
Part of paid clinical trials in Charleston, South Carolina.
- Sponsor
- Medical University of South Carolina
- Study ID
- NCT00756769
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 2 Years - N/A
- Healthy Volunteers
- Accepted
Study Details
Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by the production of autoantibodies, multiple organ involvement, and diverse clinical symptoms and immunologic manifestations. African Americans are at a disproportionately higher risk of developing SLE, develop SLE at an earlier age, and have increased morbidity and mortality compared with European Americans. Our central study hypothesis is that there are specific genetic factors that interact with environmental exposures leading to the development of SLE. The African American Gullah population from the Sea Islands of South Carolina and Georgia are unique in their genetic homogeneity with minimal non-African genetic admixture, making them an ideal cohort to address questions of environmental and genetic influence on the development and progression of SLE.
Key Dates
- Start date
- Apr 30, 2003
- Status verified
- Jul 2025
- Primary completion
- Jun 30, 2027
- Completion
- Jun 30, 2028
Study Design
- Enrollment
- 750 participants (estimated)
Arms
- Arm: 1Patients with SLE
- Arm: 2Related unaffected controls
- Arm: 3Unrelated unaffected controls
Central Contacts
- Diane L. Kamen, MD, MSCR843-792-4825
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Medical University of South Carolina | Charleston | South Carolina | 29425 | - |
Find similar trials in Charleston, SC
Related Studies
- An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric ParticipantsPHASE3 · Recruiting · AstraZeneca · Phoenix, Arizona
- RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus ErythematosusPHASE1/PHASE2 · Recruiting · Cabaletta Bio · Orange, California
- UC-MSC Cell Therapy Study for Systemic Lupus Erythematosus (SLE) PatientsPHASE1 · Recruiting · LiveKidney.Bio · Charleston, South Carolina
- Study of Systemic Lupus ErythematosusRecruiting · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) · Bethesda, Maryland